Business Medical Dialogues
    • facebook
    • twitter
    Sign in Signup
    • facebook
    • twitter
    Sign in Signup
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    Sign InRegister
    Business Medical Dialogues
    Sign inRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • SAARC nations favour...

    SAARC nations favour India-based Haslab for Homoeopathic Medicines

    Medical Dialogues BureauBy Medical Dialogues BureauPublished On 2019-07-06T09:45:34+05:30  |  Updated On 2021-08-16T16:09:23+05:30

    Haslab as they are known in the homoeopathy market, they provide various forms of homoeopathic products like eye drops, homoeopathic complex tablets, tinctures, dilutions, ointments, gels and Biochemic combinations from 1- 48.


    Mumbai: The homoeopathy product market is expected to touch USD 17.4 Billion by 2024.


    In order to tap the potential, Hahnemann Scientific Laboratory India is carving a niche for themselves, garnering orders from outside the country, mainly SAARC countries.


    Haslab as they are known in the homoeopathy market, they provide various forms of homoeopathic products like eye drops, homoeopathic complex tablets, tinctures, dilutions, ointments, gels and Biochemic combinations from 1- 48.


    If we look at the latest trends, the burgeoning popularity of alternate medical systems, especially homoeopathy is accentuating the demand for HSL products outside of India too. A team member from HSL revealed that recently they have procured a good amount of orders from the SAARC countries.


    "Homoeopathy products have gained immense popularity in recent years owing to growing acceptance of such highly individualized remedy to address specific symptoms in patient populations, the world over. We are extremely glad that other countries are now also experiencing the benefits of our products.


    Hahnemann Scientific Laboratory provide many different types of products, however, if we look at the world homoeopathy market, dilutions tend to be the most lucrative segment of all", said Amit Rastogi from Haslab.


    A recent study by 3EA, a management consulting firm that manages Haslab's marketing presence, revealed that the dilutions market is expected to reach a worth of USD 6, 253.9 million by 2024. We had a look at some more numbers, speaking about the global market, if we speak geographically, Europe is the front-runner.


    However, the Asian market is fast catching up the pace. The demand for homoeopathic products in the Asian market is expected to surge at a potentially attractive CAGR in the coming years.


    So, what makes the market so beneficial for the homoeopathy product providers? The huge rise in disposable income has turned out to be a major force in this growth. Recently, a majority of the population has shown an inclination toward alternate medical systems for the treatment of chronic ailments.


    Homoeopathy and especially Haslab has been at the crux of this development. This has turned out to be a crucial trend accentuating the demand for homoeopathic products. The burgeoning demand is supported largely by the surge in people not considering homoeopathy as a placebo anymore.


    Multiple developments in the field of medical science have also resulted in the efficacy of homoeopathy products and the growing disposable incomes, especially in emerging economies, which brings us to the SAARC countries. People in countries like Bangladesh, Bhutan, Maldives and Sri Lanka are now open to place more faith in the homeopathy as compared to the past few years. The comparison scale between allopathic and homoeopathic product satisfaction is now narrowing down more than ever.


    Well, the infeasibility of various small - and medium - scale manufacturers in the market spread across key regions to conform to good manufacturing practices might be making a minor dent, however, big market players like Haslab are leaving no stone unturned to keep the quality of products high and deliver effectively to the patients.


    "The market is expected to witness huge gains from robust promotional and marketing activities in the coming years, especially in Asia. It is a positive sign for us that we are lapping up orders from the SAARC countries in addition to our extensive presence in India", added Rastogi, explaining about the future plans on tapping huge potential and the inclination of SAARC population towards using HSL products.


    Also Read: India to set up Saarc centre to combat drug abuse menace: Revenue Secretary Hasmukh Adhia

    allopathic chronic disease complex tablets dilutions Hahnemann Scientific Laboratory Haslab Homeopathy Homoeopathic Homoeopathic Medicines HSL products India pharma pharma news pharma news india Saarc SAARC countries tinctures 
    Source : ANI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society petition

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society...

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

      Pharmaceuticals safe in PET packaging: High-level committee

      Pharmaceuticals safe in PET packaging: High-level committee

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

      NPPA fixes prices of 29 formulations under DPCO, check out details

      NPPA fixes prices of 29 formulations under DPCO, check out details

      Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

      Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 29 March 2022 11:15 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X